NCT06850792 imprOving Adherence to Pulmonary artErial hyperteNsion Treatment With teLemedicIne and patieNt guidaNce
| NCT ID | NCT06850792 |
| Status | Recruiting |
| Phase | — |
| Sponsor | University of Sao Paulo General Hospital |
| Condition | Pulmonary Arterial Hypertension (PAH) (WHO Group 1 PH) |
| Study Type | INTERVENTIONAL |
| Enrollment | 61 participants |
| Start Date | 2025-05-07 |
| Primary Completion | 2028-04 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
This trial targets 61 participants in total. It began in 2025-05-07 with a primary completion date of 2028-04.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
Pulmonary arterial hypertension (PAH) is a progressive condition with high morbidity, frequent hospitalizations, and risk of right heart failure. Despite advances in treatment, poor adherence remains a major challenge. This randomized controlled study assesses whether remote monitoring can improve treatment adherence, clinical outcomes, and side effect management in PAH patients on oral therapy.
Eligibility Criteria
Inclusion Criteria: * Adults aged ≥18 years diagnosed with pulmonary arterial hypertension (PAH) (Group 1 of the WHO classification). * Stable oral PAH therapy (including endothelin receptor antagonists, phosphodiesterase-5 inhibitors, or prostacyclin pathway agents) for at least four weeks prior to enrollment. * Ability to participate in remote teleconsultations (access to a phone or internet). * Signed informed consent agreeing to study participation. Exclusion Criteria: * Severe cognitive impairment or psychiatric disorders that could affect adherence or study participation. * Inability to communicate via phone or telemedicine due to technical or personal constraints. * Concurrent participation in another interventional clinical trial that could interfere with outcomes. * Life expectancy \<6 months due to any condition unrelated to PAH. * Pregnancy or breastfeeding.
Contact & Investigator
Frequently Asked Questions
Who can join the NCT06850792 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, studying Pulmonary Arterial Hypertension (PAH) (WHO Group 1 PH). Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT06850792 currently recruiting?
Yes, NCT06850792 is actively recruiting participants. Contact the research team at caio.cesar@hc.fm.usp.br for enrollment information.
Where is the NCT06850792 trial being conducted?
This trial is being conducted at São Paulo, Brazil.
Who is sponsoring the NCT06850792 clinical trial?
NCT06850792 is sponsored by University of Sao Paulo General Hospital. The trial plans to enroll 61 participants.